StudyRareStudyRare

Multiple acyl-CoA dehydrogenase deficiency (MADD / Glutaric aciduria type II)

Log in to star

Last updated Nov 4, 2026

Log in to add personal notes on this page.

A neonate is hypotonic with hepatomegaly and a peculiar "sweaty feet" odor. Imaging shows polycystic kidneys and dysmorphic facial features. Acylcarnitine profile is broadly abnormal across short-, medium-, and long-chain species; urine organic acids show elevated glutaric, ethylmalonic, and multiple dicarboxylic acids.

AR; ETFA or ETFB (the two subunits of electron transfer flavoprotein) or ETFDH (ETF dehydrogenase). Biallelic loss-of-function variants block electron transfer from many dehydrogenases at once.

Electron transfer flavoprotein (ETF), a heterodimer of alpha (ETFA) and beta (ETFB) subunits in the mitochondrial matrix, accepts electrons from many dehydrogenases and passes them to ETF dehydrogenase (ETFDH) in the inner membrane, which hands them to coenzyme Q in the respiratory chain. One complex serves the short-, medium-, and very long-chain acyl-CoA dehydrogenases of fatty acid oxidation, the dehydrogenases of leucine, isoleucine, valine, lysine, and tryptophan catabolism (including glutaryl-CoA dehydrogenase), and two of choline metabolism. Loss of function in any of the three genes therefore stalls all of them, which is why acylcarnitines rise at every chain length and urine carries glutaric, ethylmalonic, 2-hydroxyglutaric, and dicarboxylic acids.

Severity follows variant class in all three genes:

  • Type I, neonatal with congenital anomalies: biallelic null variants or variants that abolish mRNA, so no protein is made.
  • Type II, neonatal without anomalies: active-site or splice variants with very low residual activity.
  • Type III, late onset: at least one missense variant outside the active site, with higher residual activity.

FAD is the cofactor of both ETF and ETFDH, so high-dose riboflavin raises FAD, stabilizes ETFDH, and helps about 98% of people with late-onset disease.

electron transfer flavoprotein andETF dehydrogenaseETFA, ETFB, ETFDH;FAD-dependentmultiple acyl-CoA dehydrogenasedeficiencyelectrons from eachdehydrogenasecoenzyme Q, respiratorychain
Excerpt from fatty acid beta-oxidation. See the full pathway.

Part of fatty acid beta-oxidation.

Electron transfer from flavoprotein dehydrogenases to the respiratory chain, shared by fatty acid oxidation and several amino acid pathways.

acyl-CoA dehydrogenases of fatty acid, branched-chain amino acid, lysine, tryptophan, and choline metabolism → ETF (ETFA, ETFB) → ETF dehydrogenase (ETFDH) (the block; FAD cofactor) → coenzyme Q → respiratory chain → ATP

  • Accumulates: the substrates of every linked dehydrogenase, measured as acylcarnitines from C4 to C18:1 and urine glutaric, ethylmalonic, 2-hydroxyglutaric, and dicarboxylic acids.
  • Missing: acetyl-CoA from fat and electrons for the respiratory chain, so fasting brings hypoketotic hypoglycemia and metabolic acidosis.
  • Workbook: 5.E. Beta-oxidation of fatty acids

Three classical presentations:

  • Severe neonatal with congenital anomalies: hypotonia, hepatomegaly, cardiomyopathy, "sweaty feet" odor, polycystic kidneys, facial dysmorphism (high forehead, hypertelorism). Often fatal in the first weeks.
  • Severe neonatal without anomalies: metabolic crisis with hypoketotic hypoglycemia and acidosis.
  • Late-onset (RR-MADD): lipid-storage myopathy, exercise intolerance, episodic vomiting and weakness. Often riboflavin-responsive (riboflavin is the precursor to FAD, the cofactor for ETF).

Biochemistry:

  • Acylcarnitines: pan-elevation (C4 through C18), reflecting blockade of all chain-length dehydrogenases at once
  • Urine organic acids: glutaric, ethylmalonic, 2-hydroxyglutaric, and multiple dicarboxylic acids
  • "Sweaty feet" odor is shared with isovaleric acidemia (both accumulate short-chain volatile acids)
  • Newborn screening acylcarnitine profile shows pan-elevation across short-, medium-, and long-chain species (C4 through C18), the distinguishing pattern
  • Urine organic acids: glutaric, ethylmalonic, 2-hydroxyglutaric, and multiple dicarboxylic acids
  • Confirmation: molecular testing of ETFA, ETFB, or ETFDH
  • Avoid fasting; emergency IV glucose during illness
  • Low-fat, low-protein diet with carbohydrate emphasis
  • Riboflavin trial in any suspected MADD: dramatic responses in late-onset ETFDH disease
  • Carnitine and CoQ10 supplementation are commonly used

MADD blocks every acyl-CoA dehydrogenase at once, because the shared electron acceptor (ETF) is broken. The acylcarnitine profile lights up across every chain length, unlike isolated MCAD/VLCAD/LCHAD which elevate one specific marker.

"Sweaty feet" = MADD or IVA. Two metabolic disorders that share the odor. MADD has the broader biochemical signature; isovaleric acidemia has C5 acylcarnitine and isovaleric/isovalerylglycine on organic acids.

Glutaric aciduria type II = MADD; glutaric aciduria type I = isolated GCDH defect with macrocephaly and acute dystonic crises (a completely different disease).

Reference Links